Reports Q2 revenue $418.2M, consensus $413.15M. “Our Q2 financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams,” said CEO Jan De Witte. “Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, reliability and resilience of our manufacturing operations and supply chain. The reduction in our full-year guidance reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- IART Earnings this Week: How Will it Perform?
- Integra LifeSciences price target raised to $32 from $25 at Truist
- Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
- Integra LifeSciences Provides Updated Plans for Its Manufacturing Facility in Braintree, Massachusetts
- Integra LifeSciences provides update plans for manufacturing facility in MA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue